NCT04775745 2026-02-13
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Phase 1 Recruiting
Newave Pharmaceutical Inc
MacroGenics
National Institutes of Health Clinical Center (CC)
Stanford University